IN8bio, Inc.

IN8bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of gamma-delta T cell therapies for cancer. The company's mission, termed "Cancer Zero," aims for the complete eradication and safe elimination of all tumor cells. Headquartered in New York City at the Empire State Building, IN8bio maintains its primary scientific operations in Birmingham, Alabama.

Utilizing its proprietary DeltEx platform, IN8bio develops allogeneic, autologous, and genetically modified gamma-delta T cell product candidates. Key programs in its pipeline include INB-200, a genetically modified autologous gamma-delta T cell therapy in Phase 1 clinical trials for newly diagnosed glioblastoma (GBM), and INB-100, an allogeneic gamma-delta T cell candidate in Phase 1 for high-risk leukemias in patients undergoing haploidentical stem cell transplantation. The company also has INB-400, a Phase 2 program for newly diagnosed GBM, and preclinical programs, including a next-generation T cell engager platform.

Recent notable developments for IN8bio include the publication of clinical data from its Phase 1 INB-200 trial in The Journal of Clinical Oncology in July 2026, demonstrating extended progression-free survival in glioblastoma patients. In June 2026, the company presented updated overall survival data for its DeltEx DRI program in newly diagnosed glioblastoma at ASCO, surpassing 19.5 months, and published advances in gamma-delta T cell engineering in Nature Communications. The leadership team includes William Ho as CEO and Co-Founder, Dr. Lawrence Lamb as Executive Vice President, Chief Scientific Officer, and Co-Founder, and Kate Rochlin, who was promoted to President and Chief Operating Officer in February 2026.